Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants

Antidepressants; Nonvertebral fractures; Osteoporosis; Selective serotonin-reuptake inhibitor; Tricyclic antidepressant; Aged; Aged, 80 and over; Antidepressive Agents; Case-Control Studies; Double-Blind Method; Female; Fractures, Bone; Humans; Logistic Models; Middle Aged; Placebos; Postmenopause

Abstract :

[en] Objective: To examine the association between antidepressants, including TCAs, SSRIs, and miscellaneous antidepressants and the risk of nonvertebral fractures among women with osteoporosis. Materials and methods: This study was a post-hoc analysis of pooled data from two international, phase III, randomized, placebo-controlled, double-blind studies (the Spinal Osteoporosis Therapeutic Intervention [SOTI] and TReatment Of Peripheral OSteoporosis [TROPOS]). A nested case-control study was performed in the placebo treated population. Adjusted logistic regression models were used to estimate the risk of nonvertebral fracture associated with the use of antidepressants. Results: After 3. years of follow-up, 391 nonvertebral fractures cases were identified and matched to 1955 controls. Compared with non-users of antidepressants, antidepressants use was associated with an increased risk of nonvertebral fractures (adjusted OR=1.64; 95%CI, 1.03-2.62]). Particularly, there was a 2-fold risk increase (95%CI, 1.07-3.79) of nonvertebral fracture for current users of SSRIs and a 2.1-fold risk increase for subjects who were current users of TCAs (95%CI, 1.02-4.30). Among patients categorized as recent or past users, none of the classes of antidepressants were statistically associated with increased risk of nonvertebral fracture. Conclusions: Our findings confirm that both SSRIs and TCAs increase the risk of nonvertebral fracture in current users. © 2012 Elsevier Inc.

Disciplines :

General & internal medicine

Author, co-author :

Rabenda, Véronique ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

Bruyère, Olivier ; Université de Liège - ULiège > Département des sciences de la santé publique > Santé publique, Epidémiologie et Economie de la santé

REGINSTER, Jean-Yves ; Centre Hospitalier Universitaire de Liège - CHU > Médecine de l'appareil locomoteur

Language :

English

Title :

Risk of nonvertebral fractures among elderly postmenopausal women using antidepressants

Publication date :

2012

Journal title :

BONE

ISSN :

8756-3282

eISSN :

1873-2763

Publisher :

Elsevier, Netherlands

Volume :

Issue :

Pages :

674-679

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 18 October 2013

Statistics

Number of views

45 (7 by ULiège)

Number of downloads

2 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Moore M., Ming Yuen Ho, Dunn N., Mullee M.A., Maskell J., Kendrick T. Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database. BMJ 2009, 339:b3999.
Lockhart P., Guthrie B. Trends in primary care antidepressant prescribing 1995-2007: a longitudinal population database analysis. Br J Gen Pract 2011, 61:e565-e572.
Takeda S., Elefteriou F., Levasseur R., Liu X., Zhao L., Parker K.L., et al. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002, 111:305-317.
Elefteriou F. Neuronal signaling and the regulation of bone remodeling. Cell Mol Life Sci 2005, 62:2339-2349.
Warden S.J., Robling A.G., Sanders M.S., Bliziotes M.M., Turner C.H. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 2005, 146:685-693.
Ginzburg R., Rosero E. Risk of fractures with selective serotonin-reuptake inhibitors or tricyclic antidepressants. Ann Pharmacother 2009, 43:98-103.
Schwan S., Hallberg P. SSRIs, bone mineral density, and risk of fractures - a review. Eur Neuropsychopharmacol 2009, 19:683-692.
Haney E.M., Warden S.J., Bliziotes M.M. Effects of selective serotonin reuptake inhibitors on bone health in adults: time for recommendations about screening, prevention and management?. Bone 2010, 46:13-17.
Ray W.A., Griffin M.R., Malcolm E. Cyclic antidepressants and the risk of hip fracture. Arch Intern Med 1991, 151:754-756.
Liu B., Anderson G., Mittmann N., To T., Axcell T., Shear N. Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people. Lancet 1998, 351(9112):1303-1307.
Hubbard R., Farrington P., Smith C., Smeeth L., Tattersfield A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol 2003, 158:77-84.
Hugenholtz G.W., Heerdink E.R., van Staa T.P., Nolen W.A., Egberts A.C. Risk of hip/femur in patients using antipsychotics. Bone 2005, 37:864-870.
Vestergaard P., Rejnmark L., Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. Calcif Tissue Int 2008, 82:92-101.
Vestergaard P., Rejnmark L., Mosekilde L. Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 2006, 17:807-816.
Bolton J.M., Metge C., Lix L., Prior H., Sareen J., Leslie W.D. Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 2008, 28:384-391.
Perreault S., Dragomir A., Blais L., Moride Y., Rossignol M., Ste-Marie L.G., et al. Population-based study of the effectiveness of bone-specific drugs in reducing the risk of osteoporotic fracture. Pharmacoepidemiol Drug Saf 2008, 17:248-259.
Abrahamsen B., Brixen K. Mapping the prescriptiome to fractures in men-a national analysis of prescription history and fracture risk. Osteoporos Int 2009, 20:585-597.
van den Brand M.W., Pouwels S., Samson M.M., van Staa T.P., Thio B., Cooper C., et al. Use of anti-depressants and the risk of fracture of the hip or femur. Osteoporos Int 2009, 20:1705-1713.
Verdel B.M., Souverein P.C., Egberts T.C., van Staa T.P., Leufkens H.G., de Vries F. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010, 47:604-609.
Guo Z., Wills P., Viitanen M., Fastbom J., Winblad B. Cognitive impairment, drug use, and the risk of hip fracture in persons over 75 year old: a community-based prospective study. Am J Epidemiol 1998, 148:887-892.
Ensrud K.E., Blackwell T., Mangione C.M., Bowman P.J., Bauer D.C., Schwartz A., et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003, 163:949-957.
Richards J.B., Papaioannou A., Adachi J.D., Joseph L., Whitson H.E., Prior J.C., et al. Canadian Multicentre Osteoporosis Study Research Group. Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 2007, 167:188-194.
Spangler L., Scholes D., Brunner R.L., Robbins J., Reed S.D., Newton K.M., et al. Depressive symptoms, bone loss, and fractures in postmenopausal women. J Gen Intern Med 2008, 23:567-574.
Ziere G., Dieleman J.P., van der Cammen T.J., Hofman A., Pols H.A., Stricker B.H. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008, 28:411-417.
Nurminen J., Puustinen J., Piirtola M., Vahlberg T., Kivelä S.L. Psychotropic drugs and the risk of fractures in old age: a prospective population-based study. BMC Public Health 2010, 10:396.
Huybrechts K.F., Rothman K.J., Silliman R.A., Brookhart M.A., Schneeweiss S. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011, 183:E411-E419.
Diem S.J., Blackwell T.L., Stone K.L., Cauley J.A., Hillier T.A., Haney E.M., et al. Study of Osteoporotic Fractures Research Group. Use of antidepressant medications and risk of fracture in older women. Calcif Tissue Int 2011, 88:476-484.
Warden S.J., Robling A.G., Haney E.M., Turner C.H., Bliziotes M.M. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 2010, 46:4-12.
Haney E.M., Warden S.J. Skeletal effects of serotonin (5-hydroxytryptamine) transporter inhibition: evidence from clinical studies. J Musculoskelet Neuronal Interact 2008, 8:133-145.
Tsapakis E.M., Gamie Z., Tran G.T., Adshead S., Lampard A., Mantalaris A., et al. The adverse skeletal effects of selective serotonin reuptake inhibitors. Eur Psychiatry 2011, 10.1016/j.eurpsy.2010.10.006.
Ducy P., Karsenty G. The two faces of serotonin in bone biology. J Cell Biol 2010, 191:7-13.
Battaglino R., Fu J., Späte U., Ersoy U., Joe M., Sedaghat L., et al. Serotonin regulates osteoclast differentiation through its transporter. J Bone Miner Res 2004, 19:1420-1431.
Bliziotes M.M., Eshleman A.J., Zhang X.W., Wiren K.M. Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 2001, 29:477-486.
Meunier P.J., Roux C., Seeman E., Ortolani S., Badurski J.E., Spector T.D., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004, 350:459-468.
Reginster J.-Y., Seeman E., De Vernejoul M.C., Adami S., Compston J., Phenekos C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005, 90:2816-2822.
Wacholder S., McLaughlin J.K., Silverman D.T., Mandel J.S. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992, 135:1019-1028.
Schoofs M.W., van der Klift M., Hofman A., et al. Thiazide diuretics and the risk for hip fracture. Ann Intern Med 2003, 139:476-482.
Schlienger R.G., Kraenzlin M.E., Jick S.S., Meier C.R. Use of β-blockers and risk of fractures. JAMA 2004, 292:1326-1332.
Vestergaard P., Rejnmark L., Mosekilde L. Fracture risk associated with use of antiepileptic drugs. Epilepsia 2004, 45:1330-1337.
Liu B.A., Topper A.K., Reeves R.A., Gryfe C., Maki B.E. Falls among older people: relationship to medication use and orthostatic hypotension. J Am Geriatr Soc 1995, 43:1141-1145.
Campbell A.J. Drug treatment as a cause of falls in old age: a review of the offending agents. Drugs Aging 1991, 1:289-302.
Macdonald J.B. The role of drugs in falls in the elderly. Clin Geriat Med 1985, 1:621-636.
Rabenda V., Nicolet D., Beaudart C., Bruyère O., Reginster J.Y. Relationship between use of antidepressants and risk of fractures: a meta-analysis. Osteoporos Int 2012, 10.1007/s00198-012-2015-9.
Pacher P., Ungvari Z. Selective serotonin-reuptake inhibitor antidepressants increase the risk of falls and hip fractures in elderly people by inhibiting cardiovascular ion channels. Med Hypotheses 2001, 57:469-471.
Whooley M.A., Kip K.E., Cauley J.A., Ensrud K.E., Nevitt M.C., Browner W.S. Depression, falls, and risk of fracture in older women. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999, 159:484-490.
Christensen P., Thomsen H.Y., Pedersen O.L., Gram L.F., Kragh-Sørensen P. Orthostatic side effects of clomipramine and citalopram during treatment for depression. Psychopharmacology (Berl) 1985, 86:383-385.
Leipzig R.M., Cumming R.G., Tinetti M.E. Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs. J Am Geriatr Soc 1999, 47:30-39.
Bloch F., Thibaud M., Dugué B., Brèque C., Rigaud A.S., Kemoun G. Psychotropic drugs and falls in the elderly people: updated literature review and meta-analysis. J Aging Health 2011, 2:329-346.
Pollock B.G. Adverse reactions of antidepressants in elderly patients. J Clin Psychiatry 1999, 60(Suppl. 20):4-8.
Rodriguez de la Torre B., Dreher J., Malevany I., Bagli M., Kolbinger M., Omran H., et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001, 23:435-440.
Diem S.J., Blackwell T.L., Stone K.L., Yaffe K., Haney E.M., Bliziotes M.M., et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007, 167:1240-1245.
Williams L.J., Henry M.J., Berk M., Dodd S., Jacka F.N., Kotowicz M.A., et al. Selective serotonin reuptake inhibitor use and bone mineral density in women with a history of depression. Int Clin Psychopharmacol 2008, 23:84-87.
Kinjo M., Setoguchi S., Schneeweiss S., Solomon D.H. Bone mineral density in subjects using central nervous system-active medications. Am J Med 2005, 118:1414.
Haney E.M., Chan B.K., Diem S.J., Ensrud K.E., Cauley J.A., Barrett-Connor E., et al. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007, 167:1246-1251. for the Osteoporotic Fractures in Men Study Group.
Coelho R., Silva C., Maia A., Prata J., Barros H. Bone mineral density and depression: a community study in women. J Psychosom Res 1999, 46:29-35.
Eskandari F., Martinez P.E., Torvik S., Phillips T.M., Sternberg E.M., Mistry S., et al. Low bone mass in premenopausal women with depression. Arch Intern Med 2007, 167:2329-2336.
Wong S.Y., Lau E.M., Lynn H., Leung P.C., Woo J., Cummings S.R., et al. Depression and bone mineral density: is there a relationship in elderly Asian men? Results from MrOs (Hong Kong). Osteoporos Int 2005, 16:610-615.
Søgaard A.J., Joakimsen R.M., Tverdal A., Fønnebø V., Magnus J.H., Berntsen G.K. Long-term mental distress, bone mineral density and non-vertebral fractures. The Tromsø Study. Osteoporos Int 2005, 16:887-897.
Whitson H.E., Sanders L., Pieper C.F., Gold D.T., Papaioannou A., Richards J.B., et al. Depressive symptomatology and fracture risk in community-dwelling older men and women. Aging Clin Exp Res 2008, 20:585-592. CaMos Research Group.
Tolea M.I., Black S.A., Carter-Pokras O.D., Kling M.A. Depressive symptoms as a risk factor for osteoporosis and fractures in older Mexican American women. Osteoporos Int 2007, 18:315-322.